ReviewMarine drugs2010
Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs.
Review in Marine drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 77 citations in OpenAlex.
- Phycocompounds from Cyanobacteria: Exploring Synergistic Effects with Conventional Anticancer and Antimicrobial Properties.ACS omega · 2025Review
- Derivatization of Microcystins Can Increase Target Inhibition while Reducing Cellular Uptake.Journal of natural products · 2025Article
- The Chemistry of Phytoplankton.Chemical reviews · 2024Review
- Phytoplankton Toxins and Their Potential Therapeutic Applications: A Journey toward the Quest for Potent Pharmaceuticals.Marine drugs · 2022Review
- Natural Cyclopeptides as Anticancer Agents in the Last 20 Years.International journal of molecular sciences · 2021Review
- Antiproliferative, neurotoxic, genotoxic and mutagenic effects of toxic cyanobacterial extracts.Interdisciplinary toxicology · 2018Article
- Cyanopeptolins with Trypsin and Chymotrypsin Inhibitory Activity from the CyanobacteriumMarine drugs · 2018Article
- Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.International journal of molecular sciences · 2018Review
- Synthesis of Highly Selective Submicromolar Microcystin-Based Inhibitors of Protein Phosphatase (PP)2A over PP1.Angewandte Chemie (International ed. in English) · 2016Article
- Identification of inhibitors of biological interactions involving intrinsically disordered proteins.International journal of molecular sciences · 2015Review
- High levels of structural diversity observed in microcystins from Microcystis CAWBG11 and characterization of six new microcystin congeners.Marine drugs · 2014Article
- Cyanobacteria from terrestrial and marine sources contain apoptogens able to overcome chemoresistance in acute myeloid leukemia cells.Marine drugs · 2014Article
- Pharmacogenetics of membrane transporters: a review of current approaches.Methods in molecular biology (Clifton, N.J.) · 2014Review
- Selectivity and potency of microcystin congeners against OATP1B1 and OATP1B3 expressing cancer cells.PloS one · 2014Article
- Bioprospecting marine plankton.Marine drugs · 2013Review
- MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.Molecular cancer therapeutics · 2013Article
- Cyanobacteria and cyanotoxins: from impacts on aquatic ecosystems and human health to anticarcinogenic effects.Toxins · 2013Review
- Hepatotoxic seafood poisoning (HSP) due to microcystins: a threat from the ocean?Marine drugs · 2013Article
- Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.Journal of drug delivery · 2013Article
- Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.International journal of molecular sciences · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyanobacterial cyclopeptides, including microcystins and nodularins, are considered a health hazard to humans due to the possible toxic effects of high consumption. From a pharmacological standpoint, microcystins are stable hydrophilic cyclic heptapeptides with a potential to cause cellular damage following uptake via organic anion-transporting polypeptides (OATP). Their intracellular biological effects involve inhibition of catalytic subunits of protein phosphatase 1 (PP1) and PP2, glutathione depletion and generation of reactive oxygen species (ROS). Interestingly, certain OATPs are prominently expressed in cancers as compared to normal tissues, qualifying MC as potential candidates for cancer drug development. In the era of targeted cancer therapy, cyanotoxins comprise a rich source of natural cytotoxic compounds with a potential to target cancers expressing specific uptake transporters. Moreover, their structure offers opportunities for combinatorial engineering to enhance the therapeutic index and resolve organ-specific toxicity issues. In this article, we revisit cyanobacterial cyclopeptides as potential novel targets for anticancer drugs by summarizing existing biomedical evidence, presenting structure-activity data and discussing developmental perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.